EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bench-to-Bedside Studies of Arginine Deprivation in Cancer

George C Field, Iuliia Pavlyk, Peter W Szlosarek

Molecules · 2023

DOI: 10.3390/molecules28052150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2023. Verfasst von George C Field und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Hauptthemen laut MEDLINE: Arginine, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polaris (United States), Polaris Pharmaceuticals, Inc., charitable donations to Professor Szlosarek’s group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arginine is a semi-essential amino acid which becomes wholly essential in many cancers commonly due to the functional loss of Argininosuccinate Synthetase 1 (ASS1). As arginine is vital for a plethora of cellular processes, its deprivation provides a rationale strategy for combatting arginine-dependent cancers. Here we have focused on pegylated arginine deiminase (ADI-PEG20, pegargiminase)–mediated arginine deprivation therapy from preclinical through to clinical investigation, from monotherapy to combinations with other anticancer therapeutics. The translation of ADI-PEG20 from the first in vitro studies to the first positive phase 3 trial of arginine depletion in cancer is highlighted. Finally, this review discusses how the identification of biomarkers that may denote enhanced sensitivity to ADI-PEG20 beyond ASS1 may be realized in future clinical practice, thus personalising arginine deprivation therapy for patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArginineNeoplasmsHumansCell Line, TumorArgininosuccinate SynthaseHydrolasesPolyethylene Glycols

Stichwörter der Autor:innen

ADI-PEG20argininearginine deprivationargininosuccinate synthetase 1biomarkerscancercombination therapymonotherapy

Substanzen

ArginineArgininosuccinate SynthaseHydrolasesPolyethylene Glycols

Autor:innen und Institutionen

  • Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
  • Department of Medical Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK.

Förderung

  • Polaris (United States)
  • Polaris Pharmaceuticals, Inc.
  • charitable donations to Professor Szlosarek’s group

Zitieren

APA

Field, G. C., Pavlyk, I., & Szlosarek, P. W. (2023). Bench-to-Bedside Studies of Arginine Deprivation in Cancer. Molecules. https://doi.org/10.3390/molecules28052150

Vancouver

Field GC, Pavlyk I, Szlosarek PW. Bench-to-Bedside Studies of Arginine Deprivation in Cancer. Molecules. 2023. doi:10.3390/molecules28052150

BibTeX
@article{Field2023,
  author = {Field, George C and Pavlyk, Iuliia and Szlosarek, Peter W},
  title = {Bench-to-Bedside Studies of Arginine Deprivation in Cancer},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28052150}
}
Kostenlos starten →